Why Is Novartis Stock Gaining Monday? - Novartis (NYSE:NVS)

Why Is Novartis Stock Gaining Monday? - Novartis (NYSE:NVS)

Novartis AG (NYSE:NVS) on Monday released topline data from two Phase 3 trials, NEPTUNUS-1 and NEPTUNUS-2, evaluating ianalumab (VAY736) in adults with active Sjögren’s disease. Both trials met the primary endpoint of demonstrating statistically significant improvements in disease activity. These results support the potential for ianalumab, a drug with a dual mechanism of action, B-cell depletion and BAFF-R inhibition, to become the first target…

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease1  Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Ianalumab was well tolerated and demonstrated a […] The post Novartis announces both ianalumab Phase III clinical trials …